Investor Relations

Press Releases

Date Title/Summary View
Toggle Summary Vericel Enters into Expanded $25 Million Debt Facilities with Silicon Valley Bank and MidCap Financial to Support Accelerating MACI Uptake and Increased Epicel Usage
Facilities Include a $15 Million Term Loan and $10 Million Revolving Line of Credit CAMBRIDGE, Mass. , Dec. 07, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions,
View HTML
Toggle Summary Vericel to Present at 29th Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass. , Nov. 16, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo , president and CEO, will present the latest
View HTML
Toggle Summary Vericel Reports Third-Quarter 2017 Financial Results
Record Third Quarter Revenue of $14.3 Million Represents a 30% Increase Over Third Quarter 2016   Results Driven by Continued Momentum of MACI Uptake and Expanded Epicel Usage   Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Nov. 07, 2017 (GLOBE NEWSWIRE) --  Vericel Corporation
View HTML
Toggle Summary Vericel to Host Third-Quarter 2017 Earnings Webcast and Conference Call on November 7, 2017
CAMBRIDGE, Mass., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call: What: Vericel Corporation
View HTML
Toggle Summary Vericel Provides Business Updates at 2017 Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Oct. 05, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today provided a general business update during a previously announced webcast
View HTML
Toggle Summary Vericel to Present at the 2017 Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the Cell &
View HTML
Toggle Summary Vericel to Present at the Ladenburg Thalmann 2017 Healthcare Conference
CAMBRIDGE, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, today announced that Nick Colangelo, president and CEO, will present the latest
View HTML
Toggle Summary Vericel Reports Second-Quarter 2017 Financial Results
Revenue of $17.0 Million Represents a 32% Increase Over Second Quarter 2016 Results Driven by Momentum of MACI Uptake Following Launch   Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of
View HTML
Toggle Summary Vericel to Host Second-Quarter 2017 Earnings Webcast and Conference Call on August 9, 2017
CAMBRIDGE, Mass., July 26, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cell therapies for the treatment of patients with serious diseases and conditions, today announced the following webcast and conference call:     What: Vericel
View HTML
Toggle Summary Vericel to Host Symposium on MACI Implant for Treating Articular Cartilage Defects in the Knee at AOSSM 2017 Annual Meeting
CAMBRIDGE, Mass., July 13, 2017 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of patients with serious diseases and conditions, announced today that the company is hosting a symposium on the  MACI ® (autologous
View HTML